复方黄柏液联合美沙拉嗪对溃疡性结肠炎及肠道菌群和血清炎症因子的影响

Effect of Compound Huangbai Solution combined with oral Mesalazine on ulcerative colitis, intestinal microflora and serum inflammatory factors

摘要:

目的  探讨复方黄柏液灌肠联合美沙拉嗪口服治疗溃疡性结肠炎（UC）疗效及对患者肠道菌群和血清炎症因子的影响。方法  选取2014年1月-2014年12月于该院接受治疗的120例UC患者作为研究对象，按照随机数字表法随机分为对照组60例和观察组60例。常规治疗基础中，对照组给予美沙拉嗪口服治疗，观察组在对照组的基础上联合给予复方黄柏液灌肠治疗。随访6个月，比较两组患者临床疗效。疗程结束后，比较两组肠道菌群及血清炎症因子情况。治疗期间，观察不良反应发生情况。结果  随访6个月，观察组和对照组总有效率分别为93.3%和80.0%，组间比较差异有统计学意义（P <0.05），观察组总有效率高于对照组。疗程结束后，两组患者粪便中肠球菌、乳酸杆菌、双歧杆菌含量，肿瘤坏死因子-α（TNF-α）、白介素-6（IL-6）、白介素-8（IL-8）水平差异有统计学意义（P <0.05），观察组粪便中肠球菌、乳酸杆菌及双歧杆菌含量高于对照组，TNF-α、IL-6、IL-8水平低于对照组。结论  复方黄柏液灌肠联合美沙拉嗪口服治疗UC疗效可靠，能够提高临床疗效，有效调节肠道菌群，减轻机体炎症反应，且不良反应轻微。

Abstract:

Objective To investigate the clinical effect of Compound Huangbai Solution as an enema in combination with oral administration of Mesalazine in the treatment of ulcerative colitis (UC) and its effects on intestinal microflora and serum inflammatory factors. Methods In this study, 120 patients with UC who received therapy in our hospital from January 2014 to December 2014 were selected as research objects. According to random number table, those patients were divided into two groups equally. Besides conventional treatments, the control group was treated with oral administration of Mesalazine, while the observation group was treated with oral administration of Mesalazine and Compound Huangbai Solution as an enema. After six-month follow-up, the curative efficacy was compared between the two groups. And after the course of treatment, the content of intestinal microflora and levels of serum inflammatory factors were compared. During the treatment, the incidence of adverse reactions was observed. Results After the six-month follow-up, the observation group had a total therapeutic rate of 93.3%, which was statistically higher than that of 80.0% in the control group (P < 0.05). After the course of the treatment, the quantities of Enterococcus, Lactobacillus and Bifidobacterium in the feces in the observation group were statistically higher than those in the control group (P < 0.05). After the treatment the levels of TNF-α, IL-6 and IL-8 in the observation group were statistically lower than those in the control group (P < 0.05). During the treatment, the incidence of adverse reactions in the observation group and the control group was 10.0% and 15.0% respectively without statistical difference (P > 0.05). Conclusions Compound Huangbai Solution as an enema in combination with oral administration of Mesalazine is effective for UC, which can significantly increase curative efficacy, effectively regulate intestinal microflora and alleviate inflammatory reaction with few adverse reactions.